These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 8946479)
1. Genetic analysis of the NAT2 and CYP2D6 polymorphisms in white patients with non-insulin-dependent diabetes mellitus. Agúndez JA; Menaya JG; Tejeda R; Lago F; Chávez M; Benítez J Pharmacogenetics; 1996 Oct; 6(5):465-72. PubMed ID: 8946479 [TBL] [Abstract][Full Text] [Related]
2. Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers. Agúndez JA; Olivera M; Ladero JM; Rodriguez-Lescure A; Ledesma MC; Diaz-Rubio M; Meyer UA; Benítez J Pharmacogenetics; 1996 Dec; 6(6):501-12. PubMed ID: 9014199 [TBL] [Abstract][Full Text] [Related]
3. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Gaikovitch EA; Cascorbi I; Mrozikiewicz PM; Brockmöller J; Frötschl R; Köpke K; Gerloff T; Chernov JN; Roots I Eur J Clin Pharmacol; 2003 Aug; 59(4):303-12. PubMed ID: 12879168 [TBL] [Abstract][Full Text] [Related]
4. N-acetyltransferase-2 genotypes among Jordanian patients with diabetes mellitus. Irshaid YM; Abujbara MA; Ajlouni KM; El-Khateeb M; Jarrar YB Int J Clin Pharmacol Ther; 2013 Jul; 51(7):593-9. PubMed ID: 23587153 [TBL] [Abstract][Full Text] [Related]
5. [Polymorphism in the N-acetyltransferase 2 gene in patients with lung cancer. Short communication]. Zabost A; Roszkowska-Śliż B; Wiatr E; Radzikowska E; Rogala E; Zych J; Zwolska Z; Augustynowicz-Kopeć E; Roszkowski-Śliż K; Szczepulska-Wójcik E Pneumonol Alergol Pol; 2012; 80(4):323-8. PubMed ID: 22714076 [TBL] [Abstract][Full Text] [Related]
6. Arylamine N-acetyltransferase 2 slow acetylator polymorphisms in unrelated Iranian individuals. Bakayev VV; Mohammadi F; Bahadori M; Sheikholslami M; Javeri A; Masjedi MR; Velayati AA Eur J Clin Pharmacol; 2004 Sep; 60(7):467-71. PubMed ID: 15316701 [TBL] [Abstract][Full Text] [Related]
7. N-acetyltransferase 2 acetylation polymorphism: prevalence of slow acetylators does not differ between atopic dermatitis patients and healthy subjects. Brocvielle H; Muret P; Goydadin AC; Boone P; Broly F; Kantelip JP; Humbert P Skin Pharmacol Appl Skin Physiol; 2003; 16(6):386-92. PubMed ID: 14528063 [TBL] [Abstract][Full Text] [Related]
8. N-acetyltransferase-2 gene polymorphism as a possible biomarker for prostate cancer in Japanese men. Hamasaki T; Inatomi H; Katoh T; Aono H; Ikuyama T; Muratani T; Matsumoto T Int J Urol; 2003 Mar; 10(3):167-73. PubMed ID: 12622714 [TBL] [Abstract][Full Text] [Related]
9. NAT2 polymorphism associated with plasma glucose concentration in Canadian Oji-Cree. Hegele RA; Kwan K; Harris SB; Hanley AJ; Zinman B; Cao H Pharmacogenetics; 2000 Apr; 10(3):233-8. PubMed ID: 10803679 [TBL] [Abstract][Full Text] [Related]
10. Lack of association between human longevity and genetic polymorphisms in drug-metabolizing enzymes at the NAT2, GSTM1 and CYP2D6 loci. Muiras ML; Verasdonck P; Cottet F; Schächter F Hum Genet; 1998 May; 102(5):526-32. PubMed ID: 9654200 [TBL] [Abstract][Full Text] [Related]
11. Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population. Agúndez JA; Olivera M; Martínez C; Ladero JM; Benítez J Pharmacogenetics; 1996 Oct; 6(5):423-8. PubMed ID: 8946474 [TBL] [Abstract][Full Text] [Related]
12. Correlation of acetylator phenotype with peripheral, autonomic and central neuropathy in Northern Indian non-insulin-dependent diabetes mellitus patients. Misra A; Mittal V; Jain S; Bajaj JS Eur J Clin Pharmacol; 1999 Aug; 55(6):419-24. PubMed ID: 10492053 [TBL] [Abstract][Full Text] [Related]
13. Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) polymorphisms in breast carcinoma. Khedhaier A; Hassen E; Bouaouina N; Gabbouj S; Ahmed SB; Chouchane L BMC Cancer; 2008 Apr; 8():109. PubMed ID: 18423013 [TBL] [Abstract][Full Text] [Related]
14. Significance of the genetic polymorphism of CYP2D6 and NAT2 in patients with inflammatory bowel diseases. Dudarewicz M; Rychlik-Sych M; Barańska M; Wojtczak A; Trzciński R; Dziki A; Skrętkowicz J Pharmacol Rep; 2014 Aug; 66(4):686-90. PubMed ID: 24948072 [TBL] [Abstract][Full Text] [Related]
15. Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians. Gu J; Liang D; Wang Y; Lu C; Wu X Mutat Res; 2005 Mar; 581(1-2):97-104. PubMed ID: 15725609 [TBL] [Abstract][Full Text] [Related]
16. The N-acetyltransferase (NAT) gene: an early risk marker for diabetic nephropathy in Japanese type 2 diabetic patients? Neugebauer S; Baba T; Watanabe T; Ishizaki T; Kurokawa K Diabet Med; 1994 Oct; 11(8):783-8. PubMed ID: 7851073 [TBL] [Abstract][Full Text] [Related]
17. Expression in human prostate of drug- and carcinogen-metabolizing enzymes: association with prostate cancer risk. Agúndez JA; Martínez C; Olivera M; Gallardo L; Ladero JM; Rosado C; Prados J; Rodriguez-Molina J; Resel L; Benítez J Br J Cancer; 1998 Nov; 78(10):1361-7. PubMed ID: 9823980 [TBL] [Abstract][Full Text] [Related]
18. N-Acetyltransferase-2 (NAT2) gene polymorphisms and enzyme activity in Serbs: unprecedented high prevalence of rapid acetylators in a White population. Djordjevic N; Carrillo JA; Ueda N; Gervasini G; Fukasawa T; Suda A; Jankovic S; Aklillu E J Clin Pharmacol; 2011 Jul; 51(7):994-1003. PubMed ID: 20801937 [TBL] [Abstract][Full Text] [Related]
19. N-acetyltransferase polymorphism in patients with Behçet's disease. Aynacioglu AS; Bozkurt A; Nacak M; Kortunay S; Tunc R; Dincel A; Kayaalp SO Eur J Clin Pharmacol; 2001 Nov; 57(9):659-62. PubMed ID: 11791896 [TBL] [Abstract][Full Text] [Related]